# Citation Report

List of articles citing

## Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne: Current Evidence and Future Perspectives

DOI: 10.1007/s13555-018-0275-9
Dermatology and Therapy, 2019, 9, 19-31.

| # | Paper | IF | Citations |
|---|---|---|---|
| 46 | Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting Fusobacterium nucleatum biofilms. *Scientific Reports*, **2019**, 9, 9107 | 4.9 | 15 |
| 45 | and Acne Vulgaris: New Insights from the Integration of Population Genetic, Multi-Omic, Biochemical and Host-Microbe Studies. *Microorganisms*, **2019**, 7, | 4.9 | 52 |
| 44 | The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis. *Journal of the American Academy of Dermatology*, **2020**, 82, 222-228 | 4.5 | 16 |
| 43 | Antibiotic Resistance in Acne: Mechanisms, Complications and Management. *American Journal of Clinical Dermatology*, **2020**, 21, 813-819 | 7.1 | 5 |
| 42 | and : Two Major Sentinels of Skin Microbiota and the Influence of Cosmetics. *Microorganisms*, **2020**, 8, | 4.9 | 28 |
| 41 | The Safety and Efficacy of Phage Therapy for Superficial Bacterial Infections: A Systematic Review. *Antibiotics*, **2020**, 9, | 4.9 | 10 |
| 40 | The long-standing history of Corynebacterium parvum, immunity, and viruses. *Journal of Medical Virology*, **2020**, 92, 2429-2439 | 19.7 | 6 |
| 39 | Protecting the outside: biological tools to manipulate the skin microbiota. *FEMS Microbiology Ecology*, **2020**, 96, | 4.3 | 5 |
| 38 | Inhibitory and anti-inflammatory effects of two antimicrobial peptides moronecidin and temporin-1Dra against Propionibacterium acnes in vitro and in vivo. *Journal of Peptide Science*, **2020**, 26, e3255 | 2.1 | 3 |
| 37 | Inhibitory effect of the antimicrobial peptide BLP-7 against Propionibacterium acnes and its anti-inflammatory effect on acne vulgaris. *Toxicon*, **2020**, 184, 109-115 | 2.8 | 7 |
| 36 | Exploring the human hair follicle microbiome. *British Journal of Dermatology*, **2021**, 184, 802-815 | 4 | 22 |
| 35 | Isolation and Functional Characterization of Fusobacterium nucleatum Bacteriophage. *Methods in Molecular Biology*, **2021**, 2327, 51-68 | 1.4 | 0 |
| 34 | Treating acne with the tetracycline class of antibiotics: A review. *Dermatological Reviews*, | 0.2 | 6 |
| 33 | One-Pot, Surfactant-Free Synthesis of Gold Nanostars and Evaluation of Their Antibacterial Effects against Propionibacterium acnes. *Journal of Nanomaterials*, **2021**, 2021, 1-10 | 3.2 | 4 |
| 32 | From Dysbiosis to Healthy Skin: Major Contributions of to Skin Homeostasis. *Microorganisms*, **2021**, 9, | 4.9 | 10 |
| 31 | The effects of ALA-PDT on microbiota in pilosebaceous units of patients with severe acne: A metagenomic study. *Photodiagnosis and Photodynamic Therapy*, **2021**, 33, 102050 | 3.5 | 3 |
| 30 | Antibiotic resistance in dermatology: The scope of the problem and strategies to address it. *Journal of the American Academy of Dermatology*, **2021**, | 4.5 | 3 |

| | | | |
|---|---|---|---|
| 29 | Wastewater from the Edible Oil Industry as a Potential Source of Lipase- and Surfactant-Producing Actinobacteria. *Microorganisms*, **2021**, 9, | 4.9 | 4 |
| 28 | Acne and Microbiome. **2022**, | | |
| 27 | Regulatory Aspects of the Therapeutic Use of Bacteriophages: Europe. **2021**, 1165-1177 | | 1 |
| 26 | Acne: modern approaches to solving an old problem. *Vestnik Dermatologii I Venerologii*, **2020**, 96, 31-38 | 0.4 | |
| 25 | Acne: modern approaches to solving an old problem. *Vestnik Dermatologii I Venerologii*, **2020**, 96, 31-38 | 0.4 | |
| 24 | Regulatory Aspects of the Therapeutic Use of Bacteriophages: Europe. **2020**, 1-13 | | |
| 23 | Bacterial resistance and dermatological ramifications.. *British Journal of Dermatology*, **2022**, | 4 | 0 |
| 22 | Part I Antimicrobial resistance: Bacterial pathogens of dermatologic significance and implications of rising resistance.. *Journal of the American Academy of Dermatology*, **2022**, | 4.5 | 0 |
| 21 | The Nature and Functions of Vertebrate Skin Microbiota. **2022**, 243-265 | | |
| 20 | The potential role for phage therapy for genetic modification of cutaneous diseases.. *Clinics in Dermatology*, **2022**, | 3 | 0 |
| 19 | Towards phage therapy for acne vulgaris: Topical application in a mouse model. | | |
| 18 | Parvulan e stimolazione dell'immunità innata durante la pandemia COVID-19: la sfida?. *Gazzetta Medica Italiana Archivio Per Le Scienze Mediche*, **2022**, 180, | 0.6 | |
| 17 | Surfactin-oleogel with therapeutic potential for inflammatory acne vulgaris induced by Propionibacterium acnes.. *Applied Microbiology and Biotechnology*, **2021**, 106, 549 | 5.7 | 0 |
| 16 | Innate Immunity Stimulation during the COVID-19 Pandemic: Challenge by Parvulan.. *Journal of Immunology Research*, **2022**, 2022, 4593598 | 4.5 | |
| 15 | The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne.. *Journal of Inflammation Research*, **2022**, 15, 2795-2801 | 4.8 | 1 |
| 14 | What is new in adult acne for the last 2 years: focus on acne pathophysiology and treatments.. *International Journal of Dermatology*, **2022**, | 1.7 | 1 |
| 13 | Phage Therapy in Israel, Past, Present, and Future. *Phage*, **2022**, 3, 85-94 | 1.8 | |
| 12 | The immunomodulatory potential of phage therapy to treat acne: a review on bacterial lysis and immunomodulation. *PeerJ*, 10, e13553 | 3.1 | 3 |

| | | |
|---|---|---|
| 11 | Phage Therapy: Challenges and Opportunities. *Fine Focus*, **2022**, 8, 12-35 | 0.1 |
| 10 | Genomic and Phenotypic Characterization of Cutibacterium acnes Bacteriophages Isolated from Acne Patients. **2022**, 11, 1041 | 0 |
| 9 | In Vitro Antibacterial and Anti-Inflammatory Activity of Arctostaphylos uva-ursi Leaf Extract against Cutibacterium acnes. **2022**, 14, 1952 | 0 |
| 8 | An insight into gill microbiome of Eastern Mediterranean wild fish by applying next generation sequencing. 9, | 0 |
| 7 | Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. | 0 |
| 6 | Bacteriophage therapy as an alternative technique for treatment of multidrug-resistant bacteria causing diabetic foot infection. | 0 |
| 5 | The dynamic balance of the skin microbiome across the lifespan. | 0 |
| 4 | Phage for regenerative medicine and cosmetics. **2023**, | 0 |
| 3 | Topical phage therapy in a mouse model of Cutibacterium acnes-induced acne-like lesions. **2023**, 14, | 0 |
| 2 | The persistence and stabilization of auxiliary genes in the human skin virome. **2023**, 20, | 0 |
| 1 | Cutibacterium acnes (formerly Propionibacterium acnes): friend or foe?. | 0 |